Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 September 2020 | Story Andre Damons | Photo Pexels

Researchers from the University of the Free State (UFS) and the Central University of Technology (CUT) have recently learned that their research projects will be funded, with one research project even getting double the amount of funding requested. 

The research project of Dr Doors Fonternel, an MMed student working under Dr Edwin Turton in the Department of Anaesthesiology at the UFS, and Prof Ihar Yadroitsau (Igor Yadroitsev), Research Chair in Medical Product Development through Additive Manufacturing and the Faculty of Engineering, Built Environment and Information Technology at CUT, titled 3D Printed laryngoscope for endotracheal intubation, received R400 000 in funding. The project only requested half the amount, but in granting the funding, the evaluation committee was of the opinion that due to the relevance of the research and the long-term sustainability of the project, funding should be adjusted to R400 000.  

Another research project receiving R400 000 in funding, is a project by Dr Alice Brink, Senior Lecturer in the Department of Chemistry at the UFS, and Dr Tshepiso J Makhafola, Assistant Dean: Research, Innovation and Engagement and Senior Lecturer: Clinical Technology in the Faculty of Health and Environmental Sciences at CUT. The committee supported the novelty of the project and the contribution towards both applicants’ participation in the Future Professors’ Programme.
These projects are part of nine collaboration projects between researchers from the UFS and CUT that were approved for funding between 2019 and 2020. The funding ranges from R50 000 to R400 000. 

Using 3D printer technology 

Dr Fonternel says getting more funding than expected gives them the motivation to push through the obstacles presented by a project like this. 

“It is innovative and uncharted, so it helps to know that others also believe in the possibilities. Apart from the design, testing, and validation that this project aims to achieve, we are looking to broaden the scope into materials and sterilisation. We are also looking at acquiring equipment to enable the UFS to be able to design and manufacture devices of similar need and purpose,” says Dr Fonternel.

According to Dr Fonternel, who designed, developed, and then prototyped the video laryngoscope with the help of the Product Development and Testing Station (PDTS) at CUT, he hopes that with this new research, the validated technology of video laryngoscopy could be provided to a much larger medical community.

Prof Yadroitsau’s role is the overall project management, mechanical testing, project analysis, and possible additional fundraising.

“This can be beneficial to rural hospitals and centres with limited funds and equipment and can make a difference in the quality of care we provide to our patients. It has the potential to improve the safety of patients and healthcare workers in our current COVID-19 battle by bringing First World technology to the front line.” 

Valuable contribution to cancer research

Drs Brink and Makhafola will be collaborating on the development and testing of organometallic complexes, primarily model pharmaceuticals that can carry a radioactive metal centre. Their collaboration will develop model lead compounds and then test their biological activity, particularly for anticancer and antimicrobial activities, including toxicological profiling to determine if it is a viable option for future cancer treatment. 

“Drug development has significant challenges, particularly for academic institutions that do not have access to the focused and integrated specialty networks as developed by Big Pharma such as Roche, Novartis, Bayer, etc.  The research and development pathway of a new pharmaceutical agent that becomes commercially available, takes on average 12 years and costs approximately £1,15 bn.”

“For every single drug that receives approval, an estimated 10 000 compounds have been considered as viable options but have failed for one reason or another. Our research collaboration focuses on addressing these two main challenges that hinder academia from successfully entering the drug market.  We hope to identify potential lead compounds with novel mechanisms of action for the development of cancer therapeutics,” says Dr Brink.

This collaborative team hopes to promote and make a valuable contribution to cancer research, specifically towards the discovery of new effective cancer treatments/drugs. 

New ways of imaging patients with rheumatoid arthritis

Dr Evbuomwan Osayande, a nuclear medicine specialist at the UFS/Universitas Academic Hospital, says his research will compare the efficacy of EC-DG (ethylenedicysteine-deoxyglucose) imaging with ultrasound imaging in patients with rheumatoid arthritis. At this stage, the research is still in the protocol phase. A protocol has been submitted to the Health Sciences Research Ethics Committee of the UFS for approval. The project received R350 000. 

“If this imaging modality proves to be highly accurate and can detect disease activity, including low disease activity, much earlier than other investigational tools, it might become a routine imaging modality in the management of patients with rheumatoid arthritis,” says Dr Osayande, the principal investigator in this research.

If we can detect low disease activity with the EC-DG imaging, says Dr Osayande, it will ensure that the rheumatologists will continue patient treatment and thus prevent them from having complications, such as bone erosions and joint destruction. “It is an exciting project and we are all looking forward to the outcome.”

Embracing 4IR

The research project of Dr Thuthukile Jita, Senior Lecturer in the UFS School of Education Studies, and Dr Carlie Luzaan Schlebusch from CUT, investigates the possibilities and affordances of training student teachers to embrace the Fourth Industrial Revolution, specifically by learning to teach Science in schools using mobile devices and mobile apps. The project received R50 000 in funding.

“The study is perfectly timed amid the COVID-19 pandemic, which has resulted in large-scale disruption of schooling as we know it.  The call for teachers and learners and the education system generally to embrace technology and use information and communication technology (ICT) to continue and restore teaching and learning in some way, has been overwhelming.” 

“Consequently, there has been an almost overnight surge in the use of mobile devices for teaching and learning in schools. Sadly, the pandemic has further exposed the digital-divide reality that not all schools, teachers, and/or learners are able to engage effectively with the technology.” 

“Therefore, this study will assist in repositioning teacher preparation to use mobile devices and applications that are relevant for the topics covered in the national Curriculum and Assessment Policy Statement (CAPS) document, starting with the subject Natural Sciences for the senior phase, which include Grades 7 to 9,” says Dr Jita, who is the principal investigator of the project and who is also responsible for the conceptualisation and overall direction of the project milestones.

Research projects that have also received funding, include: 

• IoT-based early diagnostics of mobility challenges in the elderly by Elisha Markus (CUT) and Paul Kogeda (UFS). 
• Impact of urban development on environmental sustainability: Case study of Mangaung Metropolitan municipality by Dr SA Oke (CUT) and Dr Olusola Ololade (UFS).
• Promoting inclusive pedagogies through transformative learning modalities in multicultural educational settings by Dr June Palmer (CUT) and Dr Rantsie Kgothule (UFS).
• Optimisation of imaging protocols for maxillofacial reconstructive prosthesis design and modelling by Prof Deon de Beer (CUT) and Dr Jacques Janse van Rensburg (UFS).
• LET-MI-C project (Lumbar ErecTor spinae block spread using MRI and CT) by Dr Je’nine Horn-Lodewyk (CUT) and Prof Gillian Lamacraft (UFS).  

News Archive

Conference: Expanded ARV treatment
2005-03-02

VENUE: University of the Free State, Bloemfontein, South Africa
DATE: 30 March 2005 - 1 April 2005

  • ARV Programme as on 24Feb Download Word document
     
  • Programme Special events Download Word document


    Official web site www.fshealth.gov.za/subsites/arvc

     


    Rationale for the Conference
    At the time of the planned Conference, much ground would have been covered, both in the Free State and in South Africa, in respect of the expanded public sector ARV treatment programme in respect of research, experiences in practice, training of staff, treatment of patients, lessons learned, successes and failures, etc. The time would then be quite opportune to share these in a systematic manner with other provinces and countries, as well as with the large variety of stakeholders and role players in the ARV and related domains, be they academics and researchers, policy makers and service/facility managers, the variety of caregivers, and the community organisations and affected patients.

The Conference and current research
The proposed Conference is, firstly, directly linked to the current research on the public sector roll-out of ARV treatment in the Free State conducted by several research institutions (e.g. CIET, CHSR&D, UCT Lung Institute). Secondly, the Conference could and would serve as a forum for other research groups in the country and further a field to report and share knowledge and experiences on ARV treatment and related initiatives. Lastly, the Conference will stage a golden opportunity for researchers and scientists, on the one hand, and policy makers, managers, and caregivers (as knowledge users), on the other hand, to engage in cross-disciplinary discourse on this mutual and topical theme.

Theme of Conference
Expanded ARV treatment in the Free State: sharing experiences

Focus
The focus is primarily on public sector ARV treatment in the Free State, but also initiatives/activities/perspectives of relevance to the Free State elsewhere in the country at large and further a field, as well as relevant ARV initiatives in the public, private, NGO and FBO sectors. Bear in mind, however, that ARV treatment is but part of a much more comprehensive approach to HIV and AIDS. The Conference will, therefore, not narrowly focus on the ARV treatment programme only. The broader context, other relevant dimensions, and a comprehensive approach to the challenges of HIV, AIDS and TB are of equal importance.

The purpose of the Conference
Enhance meaningful exchange, mutual understanding and collaboration among researchers, scientists, policy makers, managers and practitioners in the field of ARV treatment and related fields.

Share experiences in the various spheres of ARV treatment and related spheres (policy, management, practice, research, training, public-private-civil society sectors).

Record, reflect and report on the establishment of the ARV treatment programme in the Free State, and in within the context of the comprehensive HIV/AIDS programme.

Disseminate important research results on ARV treatment and related themes to health policy makers, managers, practitioners, communities and to the research community.

Stimulate discourse among various disciplines and various stakeholders/role players involved in ARV treatment and related programmes.

Sensitise and acquaint researchers to the requirements of policy makers, managers and practitioners in respect of ARV treatment and related fields.

Facilitate the implementation of research results in ARV treatment policy, programmes and practice.

Dissemination of Conference-related information
Information generated during the Conference could feed into policy, management and practice of ARV treatment, the training accompanying such programme, and the existing body of knowledge. After the Conference the information will be disseminated via the Internet and by scientific and popular publications.

Date and duration
Set for 30 & 31 March & 1 April 2005; to commence at 09:00 on the first day (30 March) and to end at 16:30 (1 April) the third day.

Format and scope of Conference
Alternating plenary, parallel sessions and debates focused on topical issues and interest groups. The Conference will strive to be maximally interactive and participative.

Themes and topics to cover:

  • Policy, management and health services/practice (various levels and contexts – clinical treatment, information, IT systems, pharmacy, laboratories, nutrition)
     
  • Research covering all relevant disciplines and diverse dimensions of ARV treatment and related themes
  • Training and evaluation of training
  • Patients, communities and civil society organisations
  • Public, private, NGO, FBO initiatives and partnerships

Emphasis will be on the Free State, however, with of significant involvement from other provinces, SADC countries, and countries further a field. The thrust will be to export lessons and experiences from the Free State, but also to import lessons and experiences from other provinces, countries and sectors.

Presenters
Key presenters from the Free State, other provinces, South Africa, from the private, FBO and NGO sectors, and from several other countries

Delegates
About half of the delegates will be Free State stakeholders and role players (all levels and all contexts). The other half will be role players and stakeholders in the ARV and related fields from other provinces, the national level, and other countries, as well as from the private, public and non-governmental sectors.

Focused workshops
Provision will be made for half-a-day or one-day workshop initiatives on the third day (1 April 2005).

Enquiries
For more information please contact:

Prof Dingie van Rensburg
Centre for Health Systems Research & Development
University of the Free State
PO Box 339
Bloenfontein
SOUTH AFRICA
9300

Contact:
Carin van Vuuren
Conference Organiser
Centre for Health Systems Research & Development
University of the Free State
P.O.Box 339
Bloemfontein
South Africa
9300
Tel +27 (0) 51 401 2181
Fax +27 (0) 51 4480370
Cell 0832932890
e-mail: arvconference.hum@mail.uovs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept